Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact firstname.lastname@example.org.
Editor Note: For more information about this release, please scroll to bottom.
LONDON, July 10, 2014 /PRNewswire/ --
On Wednesday, July 09, 2014, the NASDAQ Composite ended at 4,419.03, up 0.63%, the Dow Jones Industrial Average advanced 0.47%, to finish the day at 16,985.61, and the S&P 500 closed at 1,972.83, up 0.46%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 712.05, up 0.38%, with the index also advancing 5.76% in the previous three months. Investor-Edge has initiated coverage on the following equities: Halozyme Therapeutics Inc. (NASDAQ: HALO), XOMA Corp. (NASDAQ: XOMA), Amicus Therapeutics Inc. (NASDAQ: FOLD) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA). Free technical research on HALO, XOMA, FOLD and ARNA can be downloaded upon signing up at:
On Wednesday, shares in Halozyme Therapeutics Inc. traded between $9.15 and $9.59 before ending the session 2.91% higher at $9.56. Halozyme Therapeutics Inc.'s stock reported a trading volume of 1.08 million shares, below its three months average volume of 2.04 million shares. Halozyme Therapeutics Inc.'s shares have advanced 4.25% in the last one month and 17.73% in the previous three months. However, the stock has lost 36.22% since the start of this year. The stock is trading above its 50-day moving average of $8.65. Moreover, shares of the company have a Relative Strength Index (RSI) of 44.75. Sign up today to read free research on HALO at:
XOMA Corp.'s stock advanced 3.40%, to close the day at $4.26. The stock recorded a trading volume of 0.93 million shares, much below its three months average volume of 1.77 million shares. The stock oscillated between $4.11 and $4.31 during the session. XOMA Corp.'s shares have declined 9.55% in the previous three trading sessions, 10.13% in the last three months and 36.70% on YTD basis. The stock is trading below its 50-day and 200-day moving averages. Moreover, the stock's 200-day moving average of $5.46 is greater than its 50-day moving average of $4.31. Additionally, the stock has an RSI of 38.35. Sign up today to read free research on XOMA at:
On Wednesday, shares in Amicus Therapeutics Inc. recorded a trading volume of 0.63 million shares, lower than its three months average volume of 1.43 million shares. The stock ended the day at $3.79, which was 1.07% above its previous day's closing of $3.75, and registered an intraday range of $3.69 and $3.84. Over the last one month and the previous three months, Amicus Therapeutics Inc.'s shares have surged 30.69% and 67.70%, respectively. Additionally, from the beginning of 2014, the company's stock has gained an upside of 61.28%. The company's stock is trading above its 50-day and 200-day moving averages of $2.63 and $2.39, respectively. Furthermore, shares of the company have an RSI of 71.58. Sign up today to read free research on FOLD at:
Arena Pharmaceuticals Inc.'s stock finished the Wednesday's session 1.20% lower at $4.95. A total of 8.17 million shares were traded, which was above its three months average volume of 5.02 million shares. The stock moved between $4.76 and $5.01 during the session. Over the previous three trading sessions and the last one month, Arena Pharmaceuticals Inc.'s shares have plummeted 15.24% and 17.09%, respectively. Additionally, the company's stock has lost 15.38% since the start of this year. The company's shares are trading below their 50-day and 200-day moving averages. Moreover, the stock's 50-day moving average of $6.22 is greater than its 200-day moving average of $6.02. Arena Pharmaceuticals Inc.'s stock has an RSI of 19.93. Sign up today to read free research on ARNA at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
©2012 PR Newswire. All Rights Reserved.